MedTrace Logo

Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease

NCT01150201 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-07-03

No results posted yet for this study

Summary

Study objective: To investigate the potential anti-proteinuric and renoprotective efficacy of aliskiren in addition to losartan in patients at risk of developing end-stage renal disease (ESRD)

Methods: This will be a randomized, double-blind study in which proteinuric, non-diabetic patients with chronic kidney disease (CKD) will be assigned in a 1:1 ratio to one of the following treatment groups for 3 years:

* Group A: Losartan (Control arm: conventional treatment)\*
* Group B: Aliskiren plus Losartan (Intervention arm)\*

* With optional addition of other anti-hypertensive agents to achieve an optimal target blood pressure of \<130/80 mmHg.

Conditions

Interventions

DRUG

Aliskiren

For CKD treatment

DRUG

Losartan

Control

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Sydney CW Tang, MD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150201 on ClinicalTrials.gov